Danazol for paroxysmal nocturnal hemoglobinuria

Review OA: closed CC0 ⤵ 3 in-corpus citations
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-10 ⓘ

Danazol therapy improved hematocrit and reduced transfusion needs in four of five patients with paroxysmal nocturnal hemoglobinuria refractory to other treatments.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal stem-cell disorder in which blood cells lack complement inhibiting membrane proteins, and become susceptible to complement-mediated injury, leading to chronic intravascular hemolysis and pancytopenia. Glucocorticoids have been a mainstay of therapy. For patients refractory to glucocorticoids and requiring blood transfusions, an alternative therapy is needed. We studied danazol therapy in 5 patients refractory to other treatments. Four of the 5 benefited, showing rise in hematocrit and eventual cessation of transfusion requirements. Remissions lasted > or =2 years in 3 and 10 years in 1 patient. Danazol was well-tolerated without serious side effects. Danazol appears to be a good alternative treatment in PNH.

My notes (saved in your browser only)

MeSH descriptors

Circadian Rhythm Danazol Hemoglobinuria, Paroxysmal Hemoglobinuria, Paroxysmal Adolescent Adult Danazol Female Hemoglobinuria, Paroxysmal Humans Male Middle Aged Remission Induction

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (30)

Cited by (3)

Source provenance

openalex
last seen: 2026-05-14T06:02:11.780192+00:00
pubmed
last seen: 2026-10-08T22:00:10.289599+00:00
unpaywall
last seen: 2026-10-13T06:25:51.201866+00:00
License: CC0 · commercial use OK